Radical alkylation of C(sp<sup>3</sup>)–H bonds with diacyl peroxides under catalyst-free conditions
作者:Hao Tian、Wentao Xu、Yuxiu Liu、Qingmin Wang
DOI:10.1039/c9cc08056b
日期:——
Herein, we describe a protocol for alkylation reactions of C(sp3)–H bonds with diacylperoxides by means of a process involving cross-coupling between an alkyl radical and an α-aminoalkyl radical. The mild, catalyst- and additive-free conditions make this protocol superior to previously reported C(sp3)–H alkylation strategies. The protocol was applied to 1,2,3,4-tetrahydroisoquinolines and a tetrahydro-β-carboline
Copper(I)-catalyzed tandem reaction: synthesis of 1,4-disubstituted 1,2,3-triazoles from alkyl diacyl peroxides, azidotrimethylsilane, and alkynes
作者:Muhammad Israr、Changqing Ye、Munira Taj Muhammad、Yajun Li、Hongli Bao
DOI:10.3762/bjoc.14.270
日期:——
A copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction for the synthesis of 1,4-disubstituted 1,2,3-triazolesfrom alkyl diacyl peroxides, azidotrimethylsilane, and terminalalkynes is reported. The alkyl carboxylic acids is for the first time being used as the alkyl azide precursors in the form of alkyl diacyl peroxides. This method avoids the necessity to handle organic azides, as they are
Alkyl Esterification of Vinylarenes Enabled by Visible-Light-Induced Decarboxylation
作者:Liang Ge、Yajun Li、Wujun Jian、Hongli Bao
DOI:10.1002/chem.201702385
日期:2017.9.4
A decarboxylative alkyl esterification of vinylarenes induced by visiblelight is described. A variety of alkyl diacyl peroxides synthesized from readily available aliphatic carboxylicacids are used as not only the oxygenation but also alkylation source. This simple and easy to handle reaction has a wide substrate scope, excellent yields, and works under mild reaction conditions. Carbon dioxide is
[EN] PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDONE CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2015096651A1
公开(公告)日:2015-07-02
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.